Linked Life Data

1000519

Source:http://linkedlifedata.com/resource/pubmed/id/1000519

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1977-2-24
pubmed:abstractText
Cis-dichlorodiammineplatinum(II) was used in the treatment of 34 patients with advanced adenocarcinoma of the ovary who were resistant to conventional chemotherapy. Two dose schedules were explored: a high-dose schedule with 30 mg/m2 given daily on 3 successive days every 4 weeks and a low-dose schedule with 30 mg/m2 given once every 2-3 weeks. Nine patients (26.5%) showed a therapeutic response with a median duration of 6 months (range, 3-15 months). The main toxic effects included myelosuppression, renal function impairment, and nausea and vomiting. The high-dose schedule proved to be more toxic without any therapeutic advantage.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0361-5960
pubmed:author
pubmed:issnType
Print
pubmed:volume
60
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
55-60
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1976
pubmed:articleTitle
Phase II study of cis-dichlorodiammineplatinum(II) (NSC-119875) in advanced adenocarcinoma of the ovary.
pubmed:publicationType
Journal Article, Clinical Trial, Randomized Controlled Trial